Peter Bains, Chief Govt Officer of Syngene Worldwide Ltd
Biocon’s contract manufacturing arm, Syngene Worldwide has posted a 3 per cent year-on-year decline in revenue after tax (PAT) to ₹183 crore for the March quarter, down from ₹189 crore in the identical interval final yr. Nonetheless, revenue for the quarter crossed the ₹1,000 crore milestone for the first time, reaching ₹1,018 crore. This marks an 8 per cent sequential development and an 11 per cent improve on a YoY foundation.
In line with Peter Bains, Managing Director and CEO, the revenue development was pushed by robust efficiency in the biologics CDMO enterprise, supported by industrial manufacturing and the addition of recent growth tasks. “After a muted first half, pushed by a sectoral downturn in US biotech funding, we’re inspired to see a return to development in the second half of the yr,” Bains mentioned.
Whereas acknowledging international uncertainties, he added, “We anticipate enterprise momentum to proceed with a pipeline construct in each small and huge molecules, supported by new pilot applications and the conversion of present pilots in discovery companies.”
Waiting for FY26, Syngene expects underlying revenue development in the early teenagers, reflecting broad-based momentum throughout analysis, growth, and manufacturing companies. Nonetheless, reported revenue development is more likely to be in the mid-single digits, after adjusting for stock balancing in massive molecule industrial manufacturing on the shopper degree.
The shares of the corporate closed at 754.00, up by 2.52 per cent on BSE.
(With inputs from BL intern Rohan Das)
Printed on April 23, 2025
Source link
#Syngene #posts #drop #PAT #revenue #crosses #time
